Adjuvant nivolumab (Opdivo) monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) compared with placebo for patients with completely resected stage IIB/C melanoma, according to a press release from Bristol Myers Squibb (BMS).
2022
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival outcomes in previously untreated patients with BRAF V600–mutant metastatic melanoma.
Relatlimab Plus Nivolumab Approved in Europe for Unresectable or Metastatic Melanoma with PD-L1 <1%
The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab (Opdivo; Opdualag) for use in the frontline treatment of adult and adolescent patients aged 12 years of age and older with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.
Why Are People With Red Hair More Prone To Skin Cancer?
Natural red hair is said to be the rarest of all hair colors. According to Rarest, approximately 1% to 2% of the global population has natural red hair, compared to the 75% to 85% who were born with natural black or dark brown hair.